According to a report by Intel Market Research, the global Livestock mRNA Vaccines Market was valued at USD 15.3 million in 2025, estimated at USD 16.7 million in 2026, and projected to reach USD 33.9 million by 2034, representing a 9.3% CAGR during 2026–2034. Livestock mRNA vaccines use messenger RNA, self-amplifying RNA or related RNA constructs to stimulate immunity against infectious diseases affecting farmed animals. The market remains at an early commercialization stage, with development increasingly focused on rapid vaccine redesign, dose efficiency, formulation stability and practical deployment across commercial herds.

Explore the full report: Livestock mRNA Vaccines Market Report

Why Is Demand Increasing?

• Rising transboundary disease risk: WOAH recorded more than 2 million animal losses associated with African swine fever between January 2022 and February 2025, increasing the commercial value of vaccine platforms capable of responding more rapidly to changing pathogens.

• Large livestock populations: China reported 429.67 million pigs in stock at the end of 2025, while Brazil had 238.18 million cattle in 2024, creating substantial addressable populations for disease-prevention technologies.

• Need for faster vaccine development: Sequence-based platforms can accelerate candidate design, while self-amplifying RNA and nanoparticle delivery are being investigated to reduce RNA requirements and improve field practicality.

Veterinary RNA Technology & Disease-Control Watch

Livestock RNA vaccine development is moving beyond platform experimentation toward practical veterinary requirements. The report highlights self-amplifying RNA, nanoparticle delivery, refrigerator-stable formulations and sequence-driven vaccine updating as important development themes. USDA-supported research is evaluating self-amplifying RNA against African swine fever and classical swine fever, including efforts targeting lower doses and improved storage stability. At the regulatory level, WOAH adopted an international African swine fever vaccine standard in May 2025 and issued field-evaluation and post-vaccination monitoring guidance in 2026. In the United States, USDA APHIS has authorized field-safety work for a bovine-specific H5N1 vaccine candidate, expanding the relevance of RNA platforms to cattle disease control.

Livestock mRNA Vaccines Market Segmentation Highlights

• By Type: Injectable Drug Administration; Non-invasive Drug Administration. Injectable delivery remains the more established route because it provides controlled dosing and fits existing veterinary-biologics infrastructure.

• By Application: Cattle; Pigs; Others. Pigs are an important development focus because of African swine fever, classical swine fever and swine influenza, while H5N1 surveillance has increased attention on cattle applications.

• By Region: North America; Europe; Asia-Pacific; Latin America; Middle East & Africa.

• Selected Countries: United States, Canada, Mexico, Germany, United Kingdom, France, China, Japan, India, South Korea, Australia, Brazil, Argentina, GCC countries and South Africa.

Regional Outlook

• North America: The largest regional market in 2025, supported by veterinary-biologics regulation, animal-health R&D, commercial livestock production and active disease surveillance.

• Europe: Benefits from established veterinary-biologics systems, intensive livestock production and cross-border disease-control requirements.

• Asia-Pacific: Offers substantial expansion potential because of its large livestock populations and exposure to transboundary animal diseases. China had 429.67 million pigs in stock at the end of 2025.

• Latin America: Large cattle and swine industries make the region commercially relevant, with Brazil reporting 238.18 million cattle and 43.91 million pigs in 2024.

• Middle East & Africa: Disease-control requirements are significant, but adoption varies according to veterinary infrastructure, purchasing power, cold-chain capabilities and regulatory capacity.

Download the free sample report: Livestock mRNA Vaccines Free Sample

Why This Market Matters

The Livestock mRNA Vaccines Market is developing around a clear veterinary need: protecting high-value animal populations against diseases that can cause substantial production, trade and biosecurity losses. Unlike established conventional vaccine categories, RNA platforms can potentially shorten the path from pathogen sequence identification to candidate design. This capability becomes particularly relevant when disease strains change or outbreaks create urgent demand for updated protection.

Commercial adoption, however, depends on more than rapid molecular design. Vaccines must demonstrate species-specific safety and efficacy while meeting strict cost requirements for large-scale livestock programs. Storage stability, administration labor, per-animal economics and compatibility with farm workflows remain central considerations. The report therefore identifies lower-dose formulations, improved thermostability and non-invasive delivery as important opportunities alongside the continued development of injectable products.

Competitive Landscape

• Merck Animal Health: Combines established animal-health infrastructure with RNA-particle capabilities and broader veterinary vaccine manufacturing and distribution resources.

• Ceva Animal Health: Brings established veterinary-biologics experience, regulatory capabilities and animal-health distribution that can support advanced-platform commercialization.

• Bayer AG: Participates through its established animal-health portfolio, manufacturing infrastructure and veterinary market relationships.

• Genvax Technologies: Focuses specifically on livestock mRNA and self-amplifying RNA technologies, including USDA-supported research in swine.

• BioNTech SE: Brings broader mRNA technology capabilities to the veterinary-platform landscape, with livestock commercialization dependent on dedicated programs, partnerships and species-specific evidence.

View the full report: Intel Market Research – Livestock mRNA Vaccines Market

Frequently Asked Questions

What is the projected size of the Livestock mRNA Vaccines Market?
The market is estimated at USD 16.7 million in 2026 and projected to reach USD 33.9 million by 2034, representing a 9.3% CAGR during 2026–2034.

Which region leads the Livestock mRNA Vaccines Market?
North America is the largest regional market in 2025, supported by established veterinary-biologics regulation, animal-health research, commercial livestock production and active disease surveillance.

What are the main trends shaping the market?
Key trends include self-amplifying RNA, nanoparticle delivery, rapid sequence-based vaccine updating, improved formulation stability and development of non-invasive administration methods.

What Does the Full Report Cover?

The complete Intel Market Research study provides quantitative market sizing and detailed analysis of the factors shaping livestock mRNA vaccine adoption through 2034. It evaluates injectable and non-invasive administration, applications across cattle, pigs and other livestock, and regional markets spanning North America, Europe, Asia-Pacific, Latin America and the Middle East & Africa. The report examines disease pressure, farm economics, regulatory requirements, storage and delivery constraints, rapid sequence-based vaccine development and self-amplifying RNA technologies. It also provides competitive intelligence covering established animal-health companies, emerging RNA developers and regional veterinary-biologics manufacturers, alongside analysis of platform positioning, strategic developments, manufacturing scalability, regulatory evidence, field validation and the factors determining commercial deployment.

View the complete report: Livestock mRNA Vaccines Market – Full Report

Download the free sample: Livestock mRNA Vaccines Market – Free Sample

About Intel Market Research

Intel Market Research provides strategic market intelligence covering market sizing, forecasting, segmentation, competitive analysis, technology trends and regional industry assessment across healthcare, biotechnology, pharmaceuticals and related industries.

Contact Details

Website: Intel Market Research
Asia-Pacific: +91 9169164321
Email: help@intelmarketresearch.com